Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma

NCT00639002 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT00639002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00639002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
July 31, 2010
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma